Lexicon Pharmaceuticals (LXRX) AI Stock Analysis

• Market Cap: $660.94M
• Dividend Yield: N/A
• Average Volume (3M): 2.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.04
• Revenue Growth: 1255.21%
• EPS Growth: 74.58%
• Country: US
• Employees: 103
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 423,680,600
• 10 Day Avg. Volume: 2,478,958
• 30 Day Avg. Volume: 2,269,142
• PEG Ratio: 0.11
• Price to Book (P/B): 3.88
• Price to Sales (P/S): 8.38
• P/FCF Ratio: -6.15
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 13.79
• Enterprise Value/Gross Profit: 13.95
• Enterprise Value/Ebitda: -16.10
• 1Y Price Target: $3.83
• Price Target Upside: 145.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.18
• Revenue Forecast (FY): $34.04M

• Rating: 60 Neutral
• Price Target: $1.50 ▼(-3.85% Downside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is driven by improving balance-sheet health and a constructive technical uptrend, supported by an earnings call that outlined multiple pipeline/regulatory catalysts and tighter cost control. Offsetting this is a still-unprofitable model with significant cash burn and a negative P/E, which keeps overall risk elevated.

Positive Factors

Licensing-driven revenue growth

Material licensing receipts demonstrate the firm's ability to monetize assets and generate near-term non-dilutive cash. Durable partner revenue can underwrite R&D and reduce sole-commercialization risk, improving the company's capacity to fund late-stage programs and strategic development.

Very high gross margins

Extremely high gross margins indicate low incremental costs to deliver product/licensing revenues. This structural margin profile supports leverage to operating leverage improvements: if R&D and SG&A are controlled, the business can move toward profitability faster once revenue scales or recurring licensing continues.

Late-stage pipeline progress

Active Phase III enrollment and Phase II-to-III readiness materially raise the probability of regulatory milestones and commercial opportunities. Late-stage progress enhances partner and acquirer interest, shortens time to value inflection, and makes future milestone/royalty streams more actionable.

Negative Factors

Declining cash reserves

A large decline in cash balances within a year tightens runway for multiple late-stage trials and development activities. This reduces flexibility to sustain parallel programs and increases the likelihood the firm must access capital markets or partners, pressuring strategic optionality.

Negative operating and free cash flows

Persistent negative operating and free cash flows reflect structural cash burn that undermines balance sheet resilience. Continued outflows necessitate external funding or meaningful expense cuts, which can constrain R&D breadth and delay commercialization even with strong top-line growth.

Regulatory uncertainty for Zynquista

Pending FDA feedback creates a meaningful sequencing risk for a core product: regulatory delays can postpone market access and revenue scaling, reduce partner confidence, and extend reliance on financing. This uncertainty materially impacts medium-term commercialization planning.

Lexicon Pharmaceuticals Business Overview & Revenue Model

Company Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

How the Company Makes Money

Lexicon Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, with Zynquista being a significant source of income following its market approval. The company also generates revenue through collaborations and partnerships with other pharmaceutical firms, which may include upfront payments, milestone payments, and royalties from product sales. Additionally, Lexicon may receive funding from research grants and other sources to support its drug development efforts. The combination of product sales, strategic partnerships, and potential licensing agreements contributes to its overall revenue stream.

Lexicon Pharmaceuticals Financial Statement Overview

Summary

Improved leverage and positive equity are major strengths (debt reduced to ~$4.6M; equity ~$107.5M). However, profitability and cash generation remain weak with a FY2025 net loss of ~$50.3M and deeply negative operating/free cash flow (~-$67.9M), keeping financing risk elevated despite revenue/licensing progress.

Income Statement

Revenue rebounded sharply in 2024 and expanded further in 2025 (to ~$49.8M), with very strong gross profit in 2025 (near break-even on direct costs). However, profitability remains weak: the company is still posting sizable operating losses and net losses (2025 net loss ~$50.3M), and margins are still negative despite a major improvement from 2024. Top-line volatility is also elevated (2025 revenue down ~29.7% vs. 2024), consistent with an uneven commercial/partner-driven revenue profile.

Balance Sheet

Leverage improved meaningfully: total debt fell from ~$108.4M (2024) to ~$4.6M (2025), bringing debt relative to equity down to a low level. Equity remains positive (~$107.5M in 2025), providing a cushion for ongoing investment. The key weakness is returns and capital efficiency—losses are still large versus equity (2025 return on equity around -47%), indicating the balance sheet is supporting a business that has not yet reached sustainable profitability.

Cash Flow

Cash generation remains a clear pressure point. Operating cash flow and free cash flow are deeply negative across the period, including 2025 operating/free cash flow of about -$67.9M, implying continued cash burn to fund operations. Cash burn improved versus 2024 (operating cash flow -$178.8M), but the business is still not self-funding and remains sensitive to future financing needs if losses persist.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	49.80M	31.08M	1.20M	139.00K	298.00K
Gross Profit	49.53M	30.46M	-57.77M	-52.38M	-54.75M
EBITDA	-48.29M	-184.29M	-169.76M	-100.03M	-86.80M
Net Income	-50.34M	-200.40M	-177.12M	-101.94M	-87.76M
Balance Sheet
Total Assets	184.99M	298.42M	229.43M	194.30M	136.91M
Cash, Cash Equivalents and Short-Term Investments	96.23M	237.96M	170.03M	138.36M	86.74M
Total Debt	62.24M	108.40M	106.06M	55.29M	2.28M
Total Liabilities	77.45M	152.47M	136.32M	77.17M	23.31M
Stockholders Equity	107.54M	145.95M	93.11M	117.12M	113.59M
Cash Flow
Free Cash Flow	-67.85M	-179.81M	-162.37M	-90.18M	-88.24M
Operating Cash Flow	-67.85M	-178.78M	-161.90M	-88.85M	-87.02M
Investing Cash Flow	113.02M	-15.38M	-49.94M	-71.08M	2.11M
Financing Cash Flow	-48.50M	238.35M	187.96M	142.21M	22.71M

Lexicon Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.56
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXRX, the sentiment is Positive. The current price of 1.56 is below the 20-day moving average (MA) of 1.60, above the 50-day MA of 1.45, and above the 200-day MA of 1.26, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 50.47 is Neutral, neither overbought nor oversold. The STOCH value of 17.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LXRX.

Lexicon Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	73 Outperform	$479.56M	0.72	240.83%	―	79.13%	2798.12%
LXRX	60 Neutral	$660.94M	-8.29	-41.94%	―	1255.21%	74.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRTA	51 Neutral	$471.04M	-2.11	-73.00%	―	-91.16%	-112.24%
BCYC	46 Neutral	$301.75M	-2.24	-33.20%	―	-23.43%	-9.84%
RGNX	45 Neutral	$418.07M	-3.83	-103.12%	―	91.30%	30.69%

Lexicon Pharmaceuticals Corporate Events

Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing

On January 29, 2026, Lexicon Pharmaceuticals entered into an underwriting agreement for a public offering of 32 million common shares at $1.30 per share and, on February 2, 2026, closed a concurrent private placement with affiliates of its largest shareholder, Invus, involving 22.4 million common shares and multiple tranches of Series B convertible preferred stock. The transactions, together priced at approximately $94.6 million in gross proceeds, strengthen Lexicon’s capital position to fund research and development and general corporate purposes, while also reinforcing Invus’s strategic stake and leading to amendments to Lexicon’s charter, including a planned increase in authorized common shares and the creation of Series B convertible preferred stock that will automatically convert into common stock once specified corporate and regulatory approvals are obtained.

The most recent analyst rating on (LXRX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.

Lexicon Pharmaceuticals Launches Equity Offering to Fund Pipeline

On January 29, 2026, Lexicon Pharmaceuticals launched an underwritten public offering of common stock, alongside a concurrent private placement to an affiliate of major shareholder Invus, L.P., to raise capital primarily for continued research and development of its drug candidates as well as working capital and general corporate purposes. The financing move comes as Lexicon advances its late-stage pipeline: the SONATA-HCM Phase 3 trial of sotagliflozin in hypertrophic cardiomyopathy is targeting 500 patients with completion of enrollment expected in mid-2026 and topline data in early 2027, pilavapadin has shown validated biological activity, clinically meaningful pain reduction and an acceptable safety profile in pooled Phase 2 data for diabetic peripheral neuropathic pain following FDA clearance to proceed to Phase 3, and the company is preparing for a potential 2026 resubmission of its ZYNQUISTA (sotagliflozin) NDA in type 1 diabetes, supported by safety data from the ongoing STENO1 study, collectively underscoring an intensifying push toward commercialization that is likely to be closely watched by investors and patients alike.

The most recent analyst rating on (LXRX) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.